source
- Atara and Pierre Fabre's T-cell therapy gets new chance for FDA approval after twice rejectedAtara Biotherapeutics and Pierre Fabre Pharmaceuticals have received notice from the U.S. FDA that it will reconsider a previously rejected T-cell therapy. The therapy, which had been turned down…
- Entrada Therapeutics' next-gen Duchenne drug fails early trial, raising competitive concernsEntrada Therapeutics reported that its next-generation exon-skipping therapy for Duchenne muscular dystrophy did not meet efficacy endpoints in an early-stage study. The trial, which evaluated the…